Innovative Treatments for Bladder Cancer: Thoughts From the Chair

Innovative Treatments for Bladder Cancer: Thoughts From the Chair is organized by PVI, PeerView Institute for Medical Education, Penn State College of Medicine.

Release Date: June 22, 2020
Expiration Date: June 21, 2021

Accreditation:
Physicians
The Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC Credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Description:
In this expert-led bladder cancer program, Dr. Arjun Balar discusses recent updates from the 2020 American Society of Clinical Oncology Annual Meeting and reviews new evidence on the continuing integration of novel therapeutics, including immunotherapy, targeted agents, and antibody-based approaches, across a wide range of bladder cancer treatment settings.

Educational Objectives:
Upon completion of this activity, participants should be better able to:
• Discuss the current therapeutic role of novel agents in advanced bladder cancer over multiple lines of treatment and across patient populations
• Summarize updated evidence about the use of novel therapies, including immune checkpoint inhibitors, targeted agents, antibody-drug conjugates, and gene therapy across the spectrum of bladder cancer settings
• Recommend patient-appropriate novel therapeutics for the management of bladder cancer
• Manage unique adverse events associated with novel immune-, targeted-, antibody-, and gene therapy-based treatments for bladder cancer